Summary

This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous
(IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal antibody, as
single agent and in combination with pembrolizumab in participants with advanced or
metastatic solid tumors and non-small cell lung cancers.

Objectives

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), also known as CD152 (cluster of
differentiation 152), is a cell surface protein receptor that interacts with B7-1 (CD80)
and B7-2 (CD86) to ensure proper function of regulatory T cells and protect host against
autoinflammatory diseases. Anti-CTLA-4 monoclonal antibodies (mAbs) have demonstrated
strong and broad cancer immunotherapeutic effects (CITE) in a variety of preclinical
models and are used clinically both as monotherapy and as part of combination therapy
with Nivolumab (anti-PD-1). However, CTLA-4 monotherapy has more immunotherapy-related
adverse effects (irAEs) than anti-PD-1/PD-L1 therapy. In addition, the rate of severe
irAE (Grades 3 and 4) reached 55% in melanoma patients receiving combination of
Ipilimumab and Nivolumab. The strong irAEs further limit the doses tolerated by cancer
patients. Nevertheless, combination with anti-PD-1 resulted in significantly improved
response rates and patient survival in multiple types of cancer. Furthermore, anti-CTLA-4
antibodies induce long-lasting immunity in cancer patients. Therefore, CTLA-4 remains an
important immunotherapy target, but major challenges remain in improving both safety and
efficacy of anti-CTLA-4 mAbs.

ONC-392 is a highly selective, humanized monoclonal IgG1-kappa isotype antibody against
CTLA-4. The parental clone was identified through in vivo screening in humanized CTLA-4
mouse model for high anti-tumor efficacy and low autoimmune toxicity. We have recently
demonstrated that ONC-392 is dissociation from CTLA-4 under low pH to allow its escape
from lysosomal degradation and recycle to cell surface. We have provided several lines of
evidence for the notion that a pH-sensitive antibody ONC-392 is not only safer but also
more effective in Treg depletion and tumor rejection than the Ipilimumab, which is
pH-insensitive. First, by preserving CTLA-4 on the cell surface, Onc-392 leaves higher
ligand density for better ADCC.

Second, Onc-392 is more efficient in Treg depletion in tumor microenvironment. Third,
Onc-392 is significantly more potent in inducing rejection of large tumors.

The study consists of four parts:

(1) The Part A study is a dose-finding rapid titration, Phase I trial of ONC-392 as a
single agent in patients with advanced or metastatic solid tumors with various histology.
The aim of this trial is to define the recommended Phase II dose for ONC-392 monotherapy
(RP2D-M). (2) The Part B study is a dose-finding phase with ONC-392 in combination with a
standard dose of 200 mg pembrolizumab in patients with advanced or metastatic solid
tumors.

(3) The Part C consists of different expansion arms.

1. Arm A: Pancreatic Cancer Cohort, ONC-392 monotherapy, will enroll
advanced/metastatic pancreatic cancer patients who have progressive disease after
first and second lines of systemic treatment.

2. Arm B: TNBC Cohort, ONC-392 monotherapy, will enroll advanced/metastatic TNBC
patients who have progressive disease after prior systemic treatments, including
checkpoint inhibitor immunotherapy.

3. Arm C: NSCLC Mono Cohort 1, ONC-392 monotherapy, will enroll advanced/metastatic
NSCLC patients with EGFR or ALK mutations who have progressive disease after prior
systemic treatments, including targeted therapy or checkpoint inhibitors.

4. Arm D: NSCLC IO Naïve Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic NSCLC cancer patients who are treatment naïve, or anti PD (L)1
immunotherapy naïve and PD-L1-positive (PD L1 TPS = 1%).

5. Arm E: NSCLC IO R/R Cohort, ONC-392/Pembrolizumab combination therapy, will enroll
advanced/metastatic NSCLC cancer patients who are R/R to prior anti-PD-(L)1
immunotherapy regardless of PD-L1 status.

6. Arm F: Melanoma IO Naïve Cohort, ONC-392/Pembrolizumab combination therapy, will
enroll advanced/metastatic Melanoma patients who are treatment naïve, or checkpoint
inhibitor immunotherapy naive. Prior systemic chemotherapy or targeted therapy are
allowed.

7. Arm G: Melanoma IO R/R Cohort, ONC-392/Pembrolizumab combination therapy, will
enroll advanced/metastatic melanoma patients who are R/R to anti-PD-(L)1
immunotherapy.

8. Arm I: NSCLC Mono Cohort 2, ONC-392 monotherapy, will enroll advanced/metastatic
NSCLC patients without EGFR or ALK mutations who have progressive disease after
prior systemic treatments, including chemotherapy or checkpoint inhibitors. Patient
must have anti-PD-(L)1 treatment, either alone or in combination, as last treatment
before enrollment. Prior anti-CTLA-4 treatment is allowed.

9. Arm J: Melanoma Mono Cohort, ONC-392 monotherapy, will enroll advanced/metastatic
melanoma patients who are R/R to anti-PD-(L)1 immunotherapy.

10. Arm K: Head and Neck Squamous Cell Carcinoma (HNSCC), ONC-392 monotherapy, will
enroll advanced/metastatic HNSCC patients with or without positive HPV who have
progressive disease after prior systemic treatments, including chemotherapy or
checkpoint inhibitors. Patient must have anti-PD-(L)1 treatment, either alone or in
combination, as last treatment before enrollment.

11. Arm L: Ovarian Cancer, ONC-392 monotherapy, will enroll patients with
advanced/metastatic ovarian cancer who have progressive disease after prior systemic
treatments, including chemotherapy, targeted therapy or checkpoint inhibitors.

12. Arm M: Solid Tumors, ONC-392 monotherapy, will enroll patients with
advanced/metastatic solid tumors who are not eligible for Arm A-C or H-L, who have
progressive disease after prior systemic treatments, including chemotherapy,
targeted therapy or checkpoint inhibitors.

13. Arm N: Renal Cell Carcinoma, ONC-392 monotherapy, will enroll advanced/metastatic
RCC patients who are R/R to anti-PD-(L)1 immunotherapy.

(4) Part D is a Phase II study in recurrent and/or metastatic adenoid cystic carcinoma
with ONC-392 monotherapy.

Eligibility

1. Inclusion Criteria: 1. . Patients must have a histological or cytological diagnosis of NSCLC or any other type of carcinoma or sarcomas, progressive metastatic disease, or progressive locally advanced disease not amenable to local therapy. 1. In the Part A Phase I dose escalation study of ONC-392 monotherapy, patients with advanced/metastatic solid tumors of any histology are eligible for participation. Please note: tumor types of primary interest in this study are malignant melanoma, renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, head and neck carcinoma, gastric carcinoma, ovarian carcinoma, colorectal cancer, any type of sarcoma. 2. In Part B dose finding of the ONC-392 plus pembrolizumab combination, patients with advanced/metastatic solid tumors of any histology that Pembrolizumab has been approval as standard of care are eligible for participation. 3. In Part C, patients with pancreatic cancer, triple negative breast cancer, non small cell lung cancer, melanoma, Head and Neck cancer, ovarian cancer, and other solid tumors are eligible. 4. In Part D, patients with recurrent and/or metastatic adenoid cystic carcinoma with disease progression within 12 months are eligible. 5. Patients must have RECIST V1.1 Measurable disease: 2. Patient is male or female and >18 years of age on day of signing informed consent. 3. Patient must have a performance status of 0 or 1 on the ECOG Performance Scale 4. Patient must have adequate organ function as indicated by the following laboratory values: Hematological: Absolute neutrophil count (ANC) =1,500 /mcL; Plateletsa =100,000 / mcL; Hemoglobin =9 g/dL or =5.6 mmol/L- without qualifications; Renal: Serum creatinine =1.5 X upper limit of normal (ULN); Hepatic: Serum total bilirubin =1.5 X ULN; OR Direct bilirubin = ULN for patients with total bilirubin levels >1.5 ULN; AST (SGOT) and ALT (SGPT) =2.5 X ULN, OR =5 X ULN for patients with active liver metastases Coagulation: International Normalized Ratio (INR) or Prothrombin Time (PT) =1.5 X ULN Activated Partial Thromboplastin Time (aPTT) =1.5 X ULN 5. Patient has voluntarily agreed to participate by giving written informed consent. 6. Female patient of childbearing potential has a negative urine or serum pregnancy test. 7. Female and Male patients must agree to use adequate methods of contraception starting with the first dose of study drug through 90 days after the last dose of study therapy. Exclusion Criteria: A patient meeting any of the following criteria is not eligible to participate in this study: 1. Patients who have not recovered to CTCAE = 1 from the AE due to cancer therapeutics. The washout period for cancer therapeutic drugs (such as chemotherapy, radioactive, or targeted therapy) is 21 days, and for antibody drug 28 days. 2. Patients who are currently enrolled in a clinical trial of an investigational agent or device. 3. Patients who are on chronic systemic steroid therapy at doses >10 mg/day 4. Patients who have active symptomatic brain metastasis or leptomeningeal metastasis. 5. Patients who have an active infection requiring systemic IV therapy within 14 days of prior to administration of ONC-392 or combined ONC-392 and Pembrolizumab. 6. Patients who have a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate, in the opinion of the treating Investigator. 7. Patients with known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial. 8. Patients who are pregnant or breastfeeding. 9. For the Part B and Part C Arm D to G, the patients that are deemed to be not suitable for Pembrolizumab.